Clinical Trial Update: Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating cryoablation and arterial infusion of SD-101 with durvalumab and tremelimumab for hepatocellular carcinoma. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• SD-101
• Tremelimumab (tremelimumab)

Snippet

Sponsor: University of California, San Diego | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: RECRUITING